Pasireotide dosage in published studies and labels

These are the doses used for Pasireotide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Pasireotide has FDA-approved human dosages. Signifor for adults with Cushing's disease is 0.3–0.9 mg under the skin twice a day, starting at 0.6 or 0.9 mg. Signifor LAR is injected into the buttock muscle every 4 weeks: 10 mg to start in Cushing's disease (up to 40 mg) and 40 mg to start in acromegaly (up to 60 mg).

FDA Approved

Dosage evidence summary for Pasireotide
Human dosing established	Yes
Route	Subcutaneous · Intramuscular
Frequency	Twice daily (Signifor); every 4 weeks (Signifor LAR)
Duration studied	Long-term while benefit continues
Titration	Signifor: adjusted to urinary free cortisol and tolerability. Signifor LAR: in acromegaly up to 60 mg after 3 months at 40 mg; in Cushing's disease up from 10 mg after 4 months, to 40 mg at most; lowered in 20 mg steps (acromegaly) for side effects.
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Pasireotide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Signifor, Cushing's diseaseFDA-approved label · FDA prescribing information	Adults with Cushing's disease for whom pituitary surgery is not an option or was not curative	Start 0.6 mg or 0.9 mg; range 0.3–0.9 mg. Child-Pugh B: start 0.3 mg, maximum 0.6 mg	Subcutaneous	Twice daily	As long as benefit is derived	Lower 24-hour urinary free cortisol	SIGNIFOR (pasireotide) injection — FDA prescribing information, DailyMed
FDA label — Signifor LAR, acromegalyFDA-approved label · FDA prescribing information	Patients with acromegaly with an inadequate response to surgery or for whom surgery is not an option	Start 40 mg; up to 60 mg after 3 months if GH or IGF-1 are not normal. Child-Pugh B: start 20 mg, maximum 40 mg	Intramuscular, gluteal, by a healthcare professional	Every 4 weeks (28 days)	Long-term	GH and IGF-1 control	SIGNIFOR LAR (pasireotide) for injectable suspension — FDA prescribing information, DailyMed
FDA label — Signifor LAR, Cushing's diseaseFDA-approved label · FDA prescribing information	Patients with Cushing's disease for whom pituitary surgery is not an option or was not curative	Start 10 mg; after 4 months may be increased up to 40 mg. Child-Pugh B: start 10 mg, maximum 20 mg	Intramuscular, gluteal, by a healthcare professional	Every 4 weeks (28 days)	Long-term	Lower 24-hour urinary free cortisol	SIGNIFOR LAR (pasireotide) for injectable suspension — FDA prescribing information, DailyMed

Where sources disagree

Signifor (twice-daily injection) and Signifor LAR (monthly depot) use different doses and routes and are not interchangeable.
Both labels call for fasting glucose, HbA1c, liver tests, an ECG and potassium and magnesium levels before starting (Signifor also lists a gallbladder ultrasound), because pasireotide can raise blood sugar. Both say to avoid use in severe hepatic impairment (Child-Pugh C).